Stockscreener 앱 받기
3.99%
전일 마감가:
$1.38
열려 있는:
$1.4
하루 거래량:
14.01M
Relative Volume:
0.94
시가총액:
$891.68M
수익:
$29.48M
순이익/손실:
$-201.19M
주가수익비율:
-4.4844
EPS:
-0.32
순현금흐름:
$-216.50M
1주 성능:
+2.50%
1개월 성능:
+3.99%
6개월 성능:
-66.00%
1년 성능:
-63.49%
1일 변동 폭
$1.37
$1.46
1주일 범위
$1.34
$1.475
52주 변동 폭
$1.17
$5.34
제론 Stock (GERN) Company Profile
명칭
Geron Corp
전화
(650) 473-7700
주소
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
GERN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.435 | 891.68M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.09 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.22 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.28 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.91 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
제론 Stock (GERN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-27 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 개시 | Leerink Partners | Outperform |
| 2024-04-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 개시 | TD Cowen | Buy |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2023-09-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-28 | 개시 | Goldman | Neutral |
| 2022-10-28 | 개시 | Wedbush | Outperform |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2021-11-02 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 재개 | B. Riley Securities | Buy |
| 2020-08-03 | 개시 | Stifel | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-09-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-04-09 | 업그레이드 | Needham | Hold → Buy |
| 2019-01-31 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 재확인 | FBR & Co. | Outperform |
| 2016-09-13 | 재확인 | FBR Capital | Outperform |
| 2015-12-07 | 재확인 | Piper Jaffray | Overweight |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-06-12 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-03-12 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2013-12-10 | 재확인 | MLV & Co | Buy |
| 2013-12-10 | 업그레이드 | Needham | Hold → Buy |
| 2013-11-08 | 재확인 | MLV & Co | Buy |
| 2013-10-16 | 개시 | MLV & Co | Buy |
| 2012-08-30 | 개시 | Stifel Nicolaus | Buy |
| 2012-06-28 | 개시 | Needham | Hold |
모두보기
제론 주식(GERN)의 최신 뉴스
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire Inc.
Shareholders that lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class Action - GlobeNewswire Inc.
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - StreetInsider
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - PrimePublishers.com
GERN INVESTOR NOTICE: Geron Corporation Investors with Substanti - GuruFocus
Shareholders that lost money on Geron Corporation(GERN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Malaysian Reserve
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in The Bancorp, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
Equinox Gold to Announce First Quarter Financial and Operating Results on May 7, 2025 - The Globe and Mail
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Levi & Korsinsky Notifies Geron Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineGERN - Stockhouse
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - The Victoria Advocate
Investors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class ActionGERN - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
The Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm - TradingView
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - StreetInsider
2025-04-20 | Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN | NDAQ:GERN | Press Release - Stockhouse
Geron Expands Team with 12 Strategic Hires, Grants $1.5M+ in Equity Awards Under Nasdaq Rule - Stock Titan
Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? - Insider Monkey
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Contact The Gross Law Firm by May 12, 2025 Deadline to Join Class Action Against Geron Corporation (GERN) - GlobeNewswire
Geron Shareholder Sues Executives Over Drug Launch Misrepresentations - USA Herald
Geron Shareholder Sues Execs Over Drug Launch Claims - Law360
Geron stock hits 52-week low at $1.19 amid sharp annual decline By Investing.com - Investing.com South Africa
Geron Brass Sued Over Cancer Drug Prospects After 32% Stock Drop - Bloomberg Law News
Geron stock hits 52-week low at $1.19 amid sharp annual decline - Investing.com Canada
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Geron Brass Sued Over Cancer Drug Prospects After Stock Drop (1) - Bloomberg Law News
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
Geron (GERN) to Announce Q1 Financial Results - GuruFocus
Geron Corporation (GERN) Faces Significant Stock Decline Amidst Volatility - GuruFocus
2025-04-13 | Shareholders that Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky About Pending Class ActionGERN | NDAQ:GERN | Press Release - Stockhouse
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
Kirby McInerney LLP Urges Investors in Geron Corporation - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN - GlobeNewswire
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire
Geron Corp (GERN) Reports Q3 2023 Financial Results and Business Highlights - GuruFocus
Geron stock touches 52-week low at $1.27 amid market challenges - Investing.com
Geron's SWOT analysis: biotech firm's stock faces growth hurdles amid promising drug developments - Investing.com
Geron’s SWOT analysis: biotech firm’s stock faces growth hurdles amid promising drug developments - Investing.com Canada
Should You Invest in Geron Corporation (GERN)? - MSN
제론 (GERN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
제론 주식 (GERN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Option Exercise |
1.19 |
287,900 |
341,693 |
155,400 |
| Feller Faye | EVP, Chief Medical Officer |
Jun 10 '24 |
Sale |
4.63 |
287,900 |
1,334,129 |
0 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Option Exercise |
1.06 |
421,875 |
447,188 |
421,875 |
| Kapur Anil | EVP, Corp Strategy & CCO |
Jun 10 '24 |
Sale |
4.64 |
421,875 |
1,959,609 |
0 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Option Exercise |
2.54 |
600,000 |
1,524,000 |
600,000 |
| SCARLETT JOHN A | Chairman, President and CEO |
Jun 04 '24 |
Sale |
4.00 |
600,000 |
2,400,000 |
600,000 |
0.27%
0.30%
자본화:
|
볼륨(24시간):